Biovie (BIVI) Non-Current Debt (2016 - 2024)
Biovie (BIVI) posted Non-Current Debt of $2.5 million for Q3 2024, down 50.0% sequentially from $5.0 million in Q2 2024, and down 15.82% YoY from $3.0 million in Q4 2023.
Biovie (BIVI) Non-Current Debt (2016 - 2024) Analysis & Trends
Biovie has reported Non-Current Debt for 8 years, with the latest figure at $2.5 million in Q3 2024.
- Quarterly Non-Current Debt fell 15.82% year-over-year to $2.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2.5 million (down 15.82% YoY) and the FY2024 annual result came in at $5.0 million, down 4.35% from the prior year.
- Non-Current Debt eased to $2.5 million in Q3 2024 per BIVI's latest filing, from $5.0 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $15.0 million in Q3 2022 and troughed at $62500.0 in Q2 2020.
- A 5-year average of $6.2 million and a median of $5.1 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt surged 18460.0% in 2022, then slumped 80.2% in 2023.
- Over 5 years, Non-Current Debt stood at $62500.0 in 2020, then soared by 17677.9% to $11.1 million in 2021, then gained by 19.35% to $13.3 million in 2022, then sank by 77.6% to $3.0 million in 2023, then fell by 15.82% to $2.5 million in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $2.5 million, $5.0 million, and $3.0 million for Q3 2024, Q2 2024, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 8.96 Bn |
| 10 | Biovie | 13.80 Mn | 13.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Sep 30, 2023 | 2.97 Mn |
| Jun 30, 2023 | 5.23 Mn |
| Mar 31, 2023 | 7.41 Mn |
| Dec 31, 2022 | 13.26 Mn |
| Sep 30, 2022 | 15.00 Mn |
| Jun 30, 2022 | 12.14 Mn |
| Mar 31, 2022 | 11.60 Mn |
| Dec 31, 2021 | 11.11 Mn |
| Mar 31, 2021 | 62,500.00 |
| Dec 31, 2020 | 62,500.00 |
| Sep 30, 2020 | 62,500.00 |
| Jun 30, 2020 | 62,500.00 |
| Jun 30, 2018 | 575,918.00 |
| Mar 31, 2018 | 575,917.00 |
| Dec 31, 2017 | 575,917.00 |
| Jun 30, 2017 | 575,918.00 |
| Dec 31, 2016 | 10,500.00 |